TY - JOUR
T1 - Upscaling of a living membrane for bioartificial kidney device
AU - Chevtchik, Natalia Vladimirovna
AU - Fedecostante, Michele
AU - Jansen, Jitske
AU - Mihajlovic, Milos
AU - Wilmer, Martijn
AU - Rüth, Marieke
AU - Masereeuw, Rosalinde
AU - Stamatialis, Dimitrios
N1 - Copyright © 2016. Published by Elsevier B.V.
PY - 2016/11/5
Y1 - 2016/11/5
N2 - The limited removal of metabolic waste products in dialyzed kidney patients leads to high morbidity and mortality. One powerful solution for a more complete removal of those metabolites might be the application of the bioartificial kidney device (BAK), which contains a hybrid "living membrane" with functional proximal tubule epithelial cells (PTEC). These cells are supported by an artificial functionalized hollow fiber membrane (HFM) and are able to actively remove the waste products. In our earlier studies, conditionally immortalized human PTEC (ciPTEC) have been shown to express functional organic cationic transporter 2 (OCT2) when seeded on small size flat or hollow fiber polyethersulfone (PES) membranes. Here, an upscaled "living membrane" is presented. We developed and assessed the functionality of modules containing three commercially available MicroPES HFM supporting ciPTEC. The HFM were optimally coated with l-Dopa and collagen IV to support a uniform and tight monolayer formation of matured ciPTEC under static culturing conditions. Both abundant expression of zonula occludens-1 (ZO-1) protein and limited diffusion of FITC-inulin confirm a clear barrier function of the monolayer. Furthermore, the uptake of 4-(4-(dimethylamino)styryl)-N-methylpyridinium iodide (ASP(+)), a fluorescent OCT substrate was studied in absence and presence of known OCT inhibitors, such as cimetidine and a cationic uremic mixture. The ASP(+) uptake by the living upscaled membrane was decreased by 60% in the presence of either inhibitor, proving the active function of the OCT2. In conclusion, this study presents a successful upscaling of a living membrane with active organic cation transport as a support for BAK device.
AB - The limited removal of metabolic waste products in dialyzed kidney patients leads to high morbidity and mortality. One powerful solution for a more complete removal of those metabolites might be the application of the bioartificial kidney device (BAK), which contains a hybrid "living membrane" with functional proximal tubule epithelial cells (PTEC). These cells are supported by an artificial functionalized hollow fiber membrane (HFM) and are able to actively remove the waste products. In our earlier studies, conditionally immortalized human PTEC (ciPTEC) have been shown to express functional organic cationic transporter 2 (OCT2) when seeded on small size flat or hollow fiber polyethersulfone (PES) membranes. Here, an upscaled "living membrane" is presented. We developed and assessed the functionality of modules containing three commercially available MicroPES HFM supporting ciPTEC. The HFM were optimally coated with l-Dopa and collagen IV to support a uniform and tight monolayer formation of matured ciPTEC under static culturing conditions. Both abundant expression of zonula occludens-1 (ZO-1) protein and limited diffusion of FITC-inulin confirm a clear barrier function of the monolayer. Furthermore, the uptake of 4-(4-(dimethylamino)styryl)-N-methylpyridinium iodide (ASP(+)), a fluorescent OCT substrate was studied in absence and presence of known OCT inhibitors, such as cimetidine and a cationic uremic mixture. The ASP(+) uptake by the living upscaled membrane was decreased by 60% in the presence of either inhibitor, proving the active function of the OCT2. In conclusion, this study presents a successful upscaling of a living membrane with active organic cation transport as a support for BAK device.
KW - Bioartificial kidney device
KW - Living membrane
KW - Functionalized hollow fiber membranes
KW - Conditionally immortalized human renal proximal tubule epithelial cells
KW - Monolayer of functional cells
U2 - 10.1016/j.ejphar.2016.07.009
DO - 10.1016/j.ejphar.2016.07.009
M3 - Article
C2 - 27395800
SN - 0014-2999
VL - 790
SP - 28
EP - 35
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
ER -